De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Aurobindo Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Aurobindo Pharma's is Kambam Reddy, benoemd in Jun2006, heeft een ambtstermijn van 18.33 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 45.05M, bestaande uit 50.9% salaris en 49.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.62% van de aandelen van het bedrijf, ter waarde ₹ 46.99B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.2 jaar en 5.4 jaar.

Belangrijke informatie

Kambam Reddy

Algemeen directeur

₹45.0m

Totale compensatie

Percentage CEO-salaris	50.9%
Dienstverband CEO	18.3yrs
Eigendom CEO	5.6%
Management gemiddelde ambtstermijn	9.2yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23

Recent updates

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Apr 14

Analyse CEO-vergoeding

Hoe is Kambam Reddy's beloning veranderd ten opzichte van Aurobindo Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	₹35b
Mar 31 2024	₹45m	₹23m	₹32b
Dec 31 2023	n/a	n/a	₹28b
Sep 30 2023	n/a	n/a	₹23b
Jun 30 2023	n/a	n/a	₹20b
Mar 31 2023	₹37m	₹19m	₹19b
Dec 31 2022	n/a	n/a	₹20b
Sep 30 2022	n/a	n/a	₹21b
Jun 30 2022	n/a	n/a	₹24b
Mar 31 2022	₹27m	₹14m	₹26b
Dec 31 2021	n/a	n/a	₹29b
Sep 30 2021	n/a	n/a	₹52b
Jun 30 2021	n/a	n/a	₹53b
Mar 31 2021	₹23m	₹20m	₹53b
Dec 31 2020	n/a	n/a	₹54b
Sep 30 2020	n/a	n/a	₹31b
Jun 30 2020	n/a	n/a	₹30b
Mar 31 2020	₹15m	₹13m	₹28b
Dec 31 2019	n/a	n/a	₹26b
Sep 30 2019	n/a	n/a	₹26b
Jun 30 2019	n/a	n/a	₹25b
Mar 31 2019	₹15m	₹13m	₹24b
Dec 31 2018	n/a	n/a	₹23b
Sep 30 2018	n/a	n/a	₹22b
Jun 30 2018	n/a	n/a	₹24b
Mar 31 2018	₹15m	₹13m	₹24b

Compensatie versus markt: De totale vergoeding ($USD 537.43K ) Kambam } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 1.09M ).

Compensatie versus inkomsten: De vergoeding van Kambam is het afgelopen jaar met meer dan 20% gestegen.

CEO

Kambam Reddy (66 yo)

18.3yrs

Tenure

₹45,048,542

Compensatie

Mr. Kambam Nithyananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Mana...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kambam Reddy	Vice Chairman & MD	18.3yrs	₹45.05m	5.62% ₹ 48.0b
Mettu Madan Reddy	Whole-Time Director	no data	₹60.15m	geen gegevens
Makkapati Satakarni	President of Biologics	8.7yrs	₹300.00k	geen gegevens
Santhanam Subramanian	Chief Financial Officer	10.3yrs	₹21.06m	geen gegevens
Sanjeev Dani	COO & Head of Formulations	9.2yrs	geen gegevens	geen gegevens
S. Kumar	President of Technical	no data	geen gegevens	geen gegevens
Arvind Bothra	Head of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
B. Reddy	Compliance Officer & Company Secretary	8.3yrs	₹4.76m	geen gegevens
G. Prasad	Senior Vice President of Global Finance & Operations	no data	geen gegevens	geen gegevens
Sudhir Singhi	Head of Global Finance Operations	no data	geen gegevens	geen gegevens
A. Rama Rao	Chief Quality Officer -Corporate QA	no data	geen gegevens	0.025% ₹ 210.0m
V. Handa	President of Chemical Research	no data	geen gegevens	geen gegevens

9.2yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AUROPHARMA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kambam Reddy	Vice Chairman & MD	37.8yrs	₹45.05m	5.62% ₹ 48.0b
Mettu Madan Reddy	Whole-Time Director	18.1yrs	₹60.15m	geen gegevens
Makkapati Satakarni	President of Biologics	less than a year	₹300.00k	geen gegevens
Penaka Venkata Reddy	Non-Executive Director	37.8yrs	₹600.00k	3.1% ₹ 26.4b
Penaka Sarath Reddy	Non-Executive Director	17.1yrs	₹900.00k	geen gegevens
Santanu Mukherjee	Independent Director	1.7yrs	₹2.50m	geen gegevens
Deepali Pant Joshi	Independent Director	no data	₹500.00k	geen gegevens
Savitha Mahajan	Additional Non-Executive Independent Director	6.8yrs	₹2.20m	geen gegevens
Venkat Chalasani	Independent Director of Apitoria Pharma Private Limited	1.5yrs	geen gegevens	geen gegevens
Mangalam Kumar	Independent Non-Executive Chairman	less than a year	geen gegevens	geen gegevens
Girish Vanvari	Non-Executive Independent Director	3.9yrs	₹2.60m	geen gegevens

5.4yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AUROPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Aurobindo Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Recent updates

Aurobindo Pharma Limited Receives USFDA Approval for Cephalexin Tablets USP, 250 Mg and 500 Mg

Aurobindo Pharma Limited (NSEI:AUROPHARMA) entered into a binding agreement to acquire remaining 49% stake in Gls Pharma Limited from Suresh Pathak and his family members for approximately INR 225 million.

Eugia Steriles Private Limited Receives Its First Product Approval by the United States Food and Drug Administration

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited Approves Interim Dividend for the Financial Year 2023-24

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Price target increased by 12% to ₹1,503

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited (NSEI:AUROPHARMA) announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.

Now 20% overvalued after recent price rise

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹956

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 8.2% to ₹721

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Consensus EPS estimates fall by 15%

Price target decreased to ₹621

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock